I
| HTA ID | Drug | Brand | Indication | Assessment status | Date | |
| - | Ixazomib | Ninlaro® | In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. | Assessment process complete | 18th December 2017 |  |
| - | Ixekizumab | Taltz® | For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. | Rapid Review Complete | 26th July 2016 | |
| - | Ixekizumab | Taltz® | For the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies | Rapid Review Complete | 20th November 2018 | |
